A Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of the MMP-12 Inhibitor FP-025 After Multiple Oral Ascending Dose Administration, and to Evaluate the Effect of Food After a Single Oral Dose Administration in Healthy Subjects

Foresee Pharmaceuticals Co., Ltd.1 个研究点分布在 1 个国家目标入组 32 人开始时间: 2017年7月21日最近更新: 2018年8月13日

适应症

干预措施

试验速览

阶段: 1 期
状态: 已完成
发起方: Foresee Pharmaceuticals Co., Ltd.
入组人数: 32
试验地点: 1
主要终点: Treatment-emergent, AEs, SAEs and ECG abnormalities up to end-of-study (EOS).

研究概览研究设计入排标准研究组 & 干预措施结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

This is a single-center, phase I study consisting of 2 parts. The first part is a multiple ascending dose (MAD) part with a randomized, double-blind, placebo-controlled design in 3 treatment groups of 8 subjects (6 active; 2 placebo). The second part is a food effect (FE) part with a randomized, open-label, 2-period, 2-way crossover, single dose design in 8 subjects.

详细描述

MAD part (Part 1)

After assessing eligibility during a 4-week screening period, subjects will be randomized to 1 of the 3 treatments as follows:

Treatment A: 14 oral doses of 100 mg FP-025 (n=6) or placebo (n=2) in 8 days.
Treatment B: 14 oral doses of 200 mg FP-025 (n=6) or placebo (n=2) in 8 days.
Treatment C: 14 oral doses of 400 mg FP-025 (n=6) or placebo (n=2) in 8 days.

FE part (Part 2)

After assessing eligibility during a 4-week screening period, 1 treatment group of 8 subjects (8 active; 0 placebo) will be randomized to a treatment sequence (D followed by E, or E followed by D):

研究设计

研究类型: Interventional
分配方式: Randomized
干预模型: Sequential
主要目的: Treatment
盲法: Double (Participant, Investigator)

盲法说明

MAD part (Part 1) - double-blind; FE part (Part 2) - open-label

入排标准

年龄范围: 18 Years 至 65 Years（Adult, Older Adult）
性别: All
接受健康志愿者: 是

入选标准

•Eligible subjects must meet all of the following inclusion criteria:
•Males aged ≥18 and ≤65 years or postmenopausal females aged ≥18 and ≤65 years, with a BMI ≥18 kg/m2 and ≤30 kg/m
•Female subjects must be of non-childbearing potential, defined as pre-menopausal females with a documented tubal ligation or hysterectomy or bilateral oophorectomy; or as post-menopausal females defined as 12 months amenorrhoea and follicle stimulating hormone (FSH) levels >40 IU/L.
•A resting pulse ≥40 bpm and ≤100 bpm at screening and on Day -
•A resting systolic blood pressure of ≤150 mmHg and a resting diastolic blood pressure of ≤95 mmHg at screening and on Day -
•Baseline laboratory test values within reference ranges based on the blood and urine samples taken at screening and on Day -
•Out of normal ranges values may be accepted by the Investigator, if not clinically significant.
•The subject is, in the opinion of the Investigator, generally healthy based on assessment of medical history, physical examination, vital signs, electrocardiogram (ECG), and the results of the haematology, clinical chemistry, urinalysis, serology, and other laboratory tests.
•Male subjects must use adequate contraception, if applicable, during the study and until 3 months after completion of the study.
•Subjects participating in the FE part of the study must be willing and able to consume the entire high-fat, high-calorie breakfast in the designated timeframe.
•Signed Informed Consent prior to any study related procedures.
•Ability to communicate well with the Investigator, in the local language, and to understand and comply with the requirements of the study.

排除标准

•Eligible subjects must meet none of the following exclusion criteria:
•The subject has taken prescription or non-prescription medication, herbal remedies, vitamins or minerals within 2 weeks prior to the first dose of study product (or within 5 half-lives prior to the first dose of study product for any medication ingested, whichever is longer).
•The subject has a substance abuse-related disorder or has a history of drug, alcohol and/or substance abuse deemed significant by the investigator.
•The subject has taken any investigational products within 60 days prior to the first dose of study product.
•The subject has a history of severe drug allergy or hypersensitivity or food allergy.
•The subject has a history or presence of any clinically significant immunological, cardiovascular, respiratory, metabolic, renal, hepatic, gastrointestinal, endocrinological (in particular diabetes or pre-diabetes), haematological, dermatological, venereal, neurological, chronic infectious or psychiatric disease or other major disorder.
•The subject has a history of cancer, other than basal cell or Stage 1 squamous cell carcinoma of the skin, which has not been in remission for at least 5 years prior to the first dose of study product.
•The subject has a history of abdominal surgery (excluding laparoscopic cholecystectomy or uncomplicated appendectomy) or thoracic or non-peripheral vascular surgery within 6 months prior to the first dose of study product.
•The subject has any concurrent illness that may affect the particular target or absorption, distribution, and elimination of the study product.
•The subject has had a clinically significant illness within 4 weeks prior to the first dose of study product.
•The subject has had surgery or trauma with significant blood loss within the last 3 months prior to the first dose of study product.
•The subject has donated blood more than 250 mL within 2 months prior to the first dose of study product.
•The subject has tested positive for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or hepatitis C virus antibody (anti-HCV).
•The subject is a current smoker or uses other nicotine containing products. Ex-smokers must have ceased smoking at least 6 months prior to the first dose of study product.
•The subject has tested positive at screening or on Day -1 for drugs of abuse or alcohol.
•A female subject who has a positive urine pregnancy test at screening or on Day -
•The subject's corrected QT interval (QTcF) (Fridericia's correction) is >450 ms as read on the printout of the ECG produced by the ECG equipment and evaluated by the Investigator at screening and on Day -
•An out-of-range or abnormal ECG may be repeated. In total, 3 ECGs should be recorded consecutively and the Investigator must evaluate the triplicate ECG. If the subject's QTcF is >450 ms on at least 2 ECGs, the subject must be excluded.
•In general, subjects should refrain from excessive physical exercise and strenuous sports activities (endurance sports) for at least 4 days before screening and Day -
•The subject is, in the opinion of the Investigator, unlikely to comply with the clinical study protocol or is unsuitable for any other reason.
•Legal incapacity or limited legal capacity at screening and on Day -
•Employees of the Investigator or study centre, as well as first degree family members of the employees or the Investigator.